Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Antiviral drugs that target host cells may work against many existing and future variants of the virus that causes COVID-19.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
One link between coronaviruses (COVID-19) and the HIV drug Kaletra dates back to the 2003 outbreak of SARS.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.